Overview
Treatment of Patients With Anxiety Disorder (0777-022)
Status:
Completed
Completed
Trial end date:
2003-02-01
2003-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of the study is to examine the safety and efficacy of MK0777 during treatment for Generalized Anxiety Disorder.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Merck Sharp & Dohme Corp.
Criteria
Inclusion Criteria:- Male and Female patients ages 18 to 70
Exclusion Criteria:
- Women who are breastfeeding or pregnant
- Positive result at prestudy on urine drug screen for illicit drugs
- History of alcohol or drug abuse